Welcome to our dedicated page for CONMED Corporation news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on CONMED Corporation stock.
CONMED Corporation (symbol: CNMD) is a global leader in medical technology, specializing in the development and sale of innovative surgical and patient monitoring products. Headquartered in Utica, New York, CONMED employs approximately 3,500 individuals who are dedicated to improving healthcare quality through high-quality product design, production, and marketing.
The company's core business encompasses a diverse range of specialties, including orthopaedics, general surgery, gynecology, gastroenterology, pulmonology, and anesthesiology. These products are known for their technological advancements, enabling physicians to deliver superior care and achieve enhanced clinical outcomes for their patients.
CONMED operates through two primary reporting units: Orthopedic Surgery and General Surgery. Geographically, the company is U.S.-centric, with the majority of its revenue generated domestically. The EMEA region contributes the second-largest revenue share, followed by APAC and the non-U.S. Americas.
The company's recent achievements include advancements in their surgical products and technology, which continue to set industry standards. Current projects are focused on enhancing product efficiency and expanding their global reach through strategic partnerships and innovations.
CONMED's mission centers around improving healthcare quality. Each employee is committed to customer satisfaction and enhanced patient outcomes, reflecting the company's core values. They strive to exhibit thoughtful leadership, provide meaningful opportunities for employees, and act as a responsible corporate citizen in the communities where they operate.
Recent news highlights include ongoing developments in their product lines and strategic initiatives to bolster market presence. With a strong financial foundation and continuous innovation, CONMED remains a pivotal player in the medical technology sector.
CONMED Corporation (NYSE: CNMD) announced that
CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair of the Board, President, and CEO, along with Todd W. Garner, Executive VP and CFO, will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 2:40 ET. Interested parties can access a live webcast through the Company’s website. CONMED specializes in providing innovative surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery.
CONMED Corporation (NYSE: CNMD) reported a 4.6% year-over-year increase in sales for Q3 2021, totaling $248.8 million. Domestic sales rose 1.6%, while international sales grew by 8.5%. Diluted EPS was $0.47, up from $0.23 in Q3 2020. Adjusted diluted EPS decreased to $0.80 from $0.88. The company adjusted its full-year revenue guidance to $1.015 billion - $1.025 billion due to ongoing pandemic impacts. Full-year adjusted diluted EPS guidance is now $3.18-$3.23, slightly revised from $3.15-$3.25.
CONMED Corporation (NYSE: CNMD) will release its financial results for the third quarter of 2021 on October 27, 2021, after the market closes. A conference call to discuss these results is scheduled for 4:30 p.m. ET on the same day. Participants can join via phone or through a webcast available on CONMED's website. The call will be re-playable from 7:30 p.m. ET on the same day until 7:30 p.m. ET on November 3, 2021.
CONMED Corporation (NYSE: CNMD) announced that Curt R. Hartman, Chair and CEO, along with CFO Todd W. Garner, will participate in a virtual fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET.
The session will be available for live viewing on the Company’s website, www.conmed.com, and can be replayed later.
CONMED specializes in surgical devices for minimally invasive procedures across various medical fields.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on October 5, 2021, to shareholders of record as of September 15, 2021. This decision reflects the company’s commitment to returning value to shareholders amidst ongoing challenges, including those presented by the COVID-19 pandemic. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various medical fields.
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q2 2021, with sales reaching $255.2 million, a 61.7% increase year over year. Domestic revenue surged 64.2%, while international sales climbed 58.6%. Diluted EPS was $0.41, up from a loss of $0.96 in Q2 2020. The company raised its full-year revenue guidance to between $1.015 billion and $1.035 billion and adjusted EPS guidance to $3.15 to $3.25, reflecting confidence in ongoing operational improvements and market recovery.
CONMED Corporation (NYSE: CNMD) is set to report its Q2 2021 financial results on July 28, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 7138188. The call will also be available via webcast on the CONMED website, and a recording will be accessible from 7:30 p.m. ET on the same day until August 4, 2021.
CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.
FAQ
What is the current stock price of CONMED Corporation (CNMD)?
What is the market cap of CONMED Corporation (CNMD)?
What does CONMED Corporation specialize in?
Where is CONMED Corporation headquartered?
How many employees does CONMED Corporation have?
What are the main product specialties of CONMED Corporation?
What are the primary reporting units of CONMED Corporation?
In which regions does CONMED Corporation generate most of its revenue?
What is the mission of CONMED Corporation?
How does CONMED Corporation ensure customer and patient satisfaction?
What recent achievements has CONMED Corporation made?
What is CONMED Corporation's approach to innovation?
